Physician profile
Todd C Malvey
NPI 1811093198
$16,480.77
in general payments reported to CMS, 2019-2025
66 companies · $3,154 in 2025
The $3,154 reported for 2025 was more than what 96% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,174 · 2020: $1,110 · 2021: $1,583 · 2022: $2,734 · 2023: $2,774 · 2024: $3,953 · 2025: $3,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,867 · Education: $13.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,866.70 |
| Education | $13.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,490.72 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,442.11 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,276.93 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $1,258.02 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,053.71 | 2019-2025 | Xarelto, Spravato |
| Gilead Sciences, INC. | $755.75 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $717.67 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $632.13 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $589.87 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $530.34 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $506.72 | 2019-2025 | Repatha, Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $435.82 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $389.10 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Alnylam Pharmaceuticals INC. | $363.96 | 2022-2025 | Onpattro, Amvuttra |
| Exact Sciences Corporation | $357.57 | 2023-2025 | Cologuard Collection Kit |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $353.48 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $325.60 | 2022-2025 | |
| Inspire Medical Systems, INC. | $257.08 | 2024-2025 | Inspire |
| Viiv Healthcare Company | $229.91 | 2019-2023 | Dovato |
| Phathom Pharmaceuticals, INC. | $215.53 | 2024-2025 | Voquezna |
| Kiniksa Pharmaceuticals International, Plc | $204.46 | 2024 | Arcalyst |
| Astellas Pharma US INC | $178.71 | 2022-2025 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $173.84 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $166.77 | 2019-2023 | Entyvio, Cuvitru |
| Abiomed | $160.06 | 2023-2025 | Impella |
| Daiichi Sankyo INC. | $138.27 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $123.23 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $119.77 | 2024-2025 | Vowst, Zenpep |
| Insmed, INC. | $115.04 | 2019-2025 | Arikayce |
| Abbott Laboratories | $110.17 | 2022-2024 | Freestyle Libre 3 |
| Scpharmaceuticals INC. | $107.46 | 2025 | |
| Dexcom, INC. | $98.32 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Janssen Biotech, INC. | $93.17 | 2019-2023 | Symtuza |
| Esperion Therapeutics, INC. | $90.24 | 2020-2025 | Nexletol |
| Sumitomo Pharma America, INC. | $80.16 | 2023-2025 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $79.37 | 2019-2021 | |
| Edwards Lifesciences Corporation | $78.89 | 2023-2025 | |
| Amarin Pharma, INC. | $74.19 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $73.80 | 2022-2024 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $71.35 | 2024 | Opsumit, Uptravi |
| Idorsia Pharmaceuticals US INC | $68.58 | 2022-2023 | Quviviq |
| Valinor Pharma, LLC | $67.94 | 2023-2025 | Movantik |
| Ardelyx, INC. | $60.69 | 2024-2025 | Ibsrela |
| Kiniksa Pharmaceuticals, LTD. | $59.25 | 2022-2023 | Arcalyst |
| Vertex Pharmaceuticals Incorporated | $52.03 | 2024-2025 | |
| Redhill Biopharma INC. | $49.19 | 2020 | |
| Madrigal Pharmaceuticals | $48.27 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $47.18 | 2021-2024 | Sutab, Suflave |
| Biodelivery Sciences International, INC. | $45.91 | 2019-2020 | |
| Corium, LLC | $45.18 | 2023 | Azstarys |
| Lundbeck LLC | $43.45 | 2022-2023 | Rexulti |
| Eisai INC. | $42.51 | 2021 | |
| Allergan, INC. | $41.12 | 2019-2020 | |
| Invivyd INC | $34.54 | 2025 | Pemgarda |
| Agios Pharmaceuticals, INC. | $30.45 | 2025 | Pyrukynd |
| Theratechnologies INC. | $29.54 | 2025 | Trogarzo, Egrifta |
| Baxter Healthcare | $27.88 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Antares Pharma, INC. | $23.38 | 2022 | |
| Collegium Pharmaceutical, INC. | $21.67 | 2021 | |
| Shield Therapeutics INC | $20.58 | 2023 | Accrufer |
| Paratek Pharmaceuticals, INC. | $20.00 | 2024 | Nuzyra |
| Regeneron Healthcare Solutions, INC. | $19.85 | 2022 | |
| Seqirus USA INC | $17.50 | 2024 | Fluad, Flucelvax |
| Ferring Pharmaceuticals INC. | $16.78 | 2025 | Rebyota |
| Sanofi Pasteur INC. | $15.01 | 2020 | |
| Xeris Pharmaceuticals, INC. | $13.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Malvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.